Американское общество гирудотерапии

Bdellastasin, a serine protease inhibitor of the antistasin family from the medical leech

Biochemistry study published in European Journal of Biochemistry (1998)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportГеномика и протеомикаФармакология секрета слюнных желёзMoser M et al. · European journal of biochemistry, 1998

Abstract

We have reported earlier the isolation and amino acid composition of bdellin A from medical leech, and characterised it as an inhibitor of trypsin, plasmin and acrosin [Fritz, H., Gebhardt, M., Meister, R. & Fink, E. (1971) in Proceedings of the international research conference on proteinase inhibitors (Fritz, H. & Tschesche, H., eds) pp. 271-280, Walter de Gruyter, Berlin]. In the present study, one of several chromatographic forms of this inhibitor was isolated from a semi-pure preparation. Elucidation of its amino acid sequence revealed that bdellin A is a member of the antistasin family. Therefore, it was renamed bdellastasin to avoid confusion with bdellin B, which is another trypsin-plasmin inhibitor from the medical leech, but of the Kazal type. Furthermore, a synthetic gene of bdellastasin was constructed, and the protein expressed in Saccharomyces cerevisiae with yields of 29 mg/l. The recombinant bdellastasin was purified by hydrophobic interaction and anion-exchange chromatography. Comparison by mass spectroscopy, far-ultraviolet circular dichroism studies, sequence determination, and inhibition characteristics demonstrated the identity of recombinant and native bdellastasin. The Ki values of bdellastasin for inhibition of bovine trypsin and human plasmin are in the nanomolar range; no inhibition was detected for factor Xa, thrombin, tissue kallikrein, plasma kallikrein and chymotrypsin. Circular dichroism analyses indicated that bdellastasin is devoid of secondary-structural elements.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsBase SequenceCattleCircular DichroismCloning, MolecularDNA PrimersGene ExpressionGenetic VectorsHumansInvertebrate HormonesLeechesOrganic Chemicals

Резюме

First isolation and characterization of bdellastasin from Hirudo medicinalis — antistasin-family inhibitor expressed in yeast for structural and functional studies.

Почему это важно для гирудотерапии

This study isolated a chromatographic form of bdellin A from the medical leech, determined its amino acid sequence, and renamed it bdellastasin upon confirming membership in the antistasin family. A synthetic bdellastasin gene was expressed in Saccharomyces cerevisiae at 29 mg/L, and the recombinant protein was shown to be identical to native bdellastasin by mass spectrometry, circular dichroism, sequencing, and inhibition profiling. Bdellastasin inhibits bovine trypsin and human plasmin with nanomolar Ki values but shows no inhibition of factor Xa, thrombin, tissue or plasma kallikrein, or chymotrypsin, and circular dichroism indicates an absence of regular secondary structure. This is relevant to ASH as a molecular characterization of a medicinal-leech secretome component with established recombinant expression. The study is limited to biochemical characterization; no in-vivo or clinical data are reported.

Цитирование

Bdellastasin, a serine protease inhibitor of the antistasin family from the medical leech.

Moser M et al. · European journal of biochemistry, 1998

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.